Fig. 1: EP₂/EP₄ deficiency permits CD8⁺ T cell-mediated tumour immune control.

a, Tumour growth profiles of 2 × 10⁵ Ptgs1/Ptgs2^−/− or control BRAF^V600E melanoma cells transplanted into WT mice, Ptger2^−/−Ptger4^fl/fl mice and Cd4^crePtger2^−/−Ptger4^fl/fl mice (n = 10 each). b, Growth profiles of 2 × 10⁶ Panc02 cells transplanted into WT mice, Ptger2^−/−Ptger4^fl/fl mice and Cd4^crePtger2^−/−Ptger4^fl/fl mice (n = 8 each). c–e, WT mice, Ptger2^−/−Ptger4^fl/fl mice and Cd4^crePtger2^−/−Ptger4^fl/fl mice were subcutaneously (s.c.) injected with 2 × 10⁶ control or Ptgs1/Ptgs2^−/− BRAF^V600E cells and TILs were analysed 11 days later by flow cytometry. c, Plots showing the frequencies of CD8⁺ and CD4⁺ TILs among CD45⁺ immune cells and expression of the activation marker CD44. d, Quantification of TIL numbers (CD8⁺ TILs: Ptgs1/Ptgs2^−/− into WT, n = 9; control into WT, n = 10; control into Ptger2^−/−Ptger4^fl/fl, n = 7; control into Cd4^crePtger2^−/−Ptger4^fl/fl, n = 10; CD4⁺ TILs: Ptgs1/Ptgs2^−/− into WT, n = 8; control into WT, n = 10; control into Ptger2^−/−Ptger4^fl/fl; n = 7; control into Cd4^crePtger2^−/−Ptger4^fl/fl, n = 8). e, TIL frequencies (Ptgs1/Ptgs2^−/− into WT, n = 8; control into WT, n = 8; control into Ptger2^−/−Ptger4^fl/fl, n = 7; control into Cd4^crePtger2^−/−Ptger4^fl/fl, n = 8). f, Effect of CD8⁺ and CD4⁺ T cell depletion on control BRAF^V600E tumour growth in Cd4^crePtger2^−/−Ptger4^fl/fl mice (Cd4^crePtger2^−/−Ptger4^fl/fl, n = 8; WT, n = 9). Data in a, b and d–f are pooled from two (b,f) or three (a,d,e) independent experiments and depicted as the mean ± s.e.m. Plots in c show data for 1 tumour representative of n = 7 tumours from 2 independent experiments. P values are from two-way analysis of variance (ANOVA) with Bonferroni’s correction for multiple testing (a,b,f) or one-way ANOVA with Dunnett’s multiple-comparison test (d,e). NS, not significant (P ≥ 0.05).

Source Data